We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SuperNova Diagnostics® Secures European Partnership with Concile, GmbH

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SuperNova Diagnostics® Secures European Partnership with Concile, GmbH"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Under terms of the agreement, SuperNova will develop and manufacture the point-of-care test product, secure regulatory approvals and co-promote the product in the European market. SuperNova will receive upfront payments, milestone development payments and a revenue-sharing sales deal for all sales in the European Union (EU). SuperNova will retain 100 percent of marketing rights outside of the EU and has the ability to sub-license or sell directly. Other terms of the deal were not disclosed.

Franz Maier, Managing Director of Concile, said, "SuperNova's technology is a perfect fit to our specially diagnostics business in Europe, and we look forward to adding additional tests to the partnership over the coming year."

Neil J. Campbell, President & CEO of SuperNova, commented, "The partnership and sales reach of Concile gives us a focused entry into the European market with an established leader and also allows us to build our commercial business into other markets."